Primary dysmenorrhea : Advances in pathogenesis and management
Primary dysmenorrhea is painful menstrual cramps without any evident pathology to account for them, and it occurs in up to 50% of menstruating females and causes significant disruption in quality of life and absenteeism. Current understanding implicates an excessive or imbalanced amount of prostanoi...
Gespeichert in:
Veröffentlicht in: | Obstetrics and gynecology (New York. 1953) 2006-08, Vol.108 (2), p.428-441 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 441 |
---|---|
container_issue | 2 |
container_start_page | 428 |
container_title | Obstetrics and gynecology (New York. 1953) |
container_volume | 108 |
creator | YUSOFF DAWOOD, M |
description | Primary dysmenorrhea is painful menstrual cramps without any evident pathology to account for them, and it occurs in up to 50% of menstruating females and causes significant disruption in quality of life and absenteeism. Current understanding implicates an excessive or imbalanced amount of prostanoids and possibly eicosanoids released from the endometrium during menstruation. The uterus is induced to contract frequently and dysrhythmically, with increased basal tone and increased active pressure. Uterine hypercontractility, reduced uterine blood flow, and increased peripheral nerve hypersensitivity induce pain. Diagnosis rests on a good history with negative pelvic evaluation findings. Evidence-based data support the efficacy of cyclooxygenase inhibitors, such as ibuprofen, naproxen sodium, and ketoprofen, and estrogen-progestin oral contraceptive pills (OCPs). Cyclooxygenase inhibitors reduce the amount of menstrual prostanoids released, with concomitant reduction in uterine hypercontractility, while OCPs inhibit endometrial development and decrease menstrual prostanoids. An algorithm is provided for a simple approach to the management of primary dysmenorrhea. |
doi_str_mv | 10.1097/01.AOG.0000230214.26638.0c |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68697344</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68697344</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-90acde8b5e2d6120eba2d03382c610ae4b831d8c0c51d9d08c4f4ce49db790753</originalsourceid><addsrcrecordid>eNpFkE1Lw0AQhhdRbK3-BQmC3hJnP5psPAilaBUK9aDgbdnsTtpIPupuKvTfu9pA5zKHed4Z5iHkhkJCIc_ugSaz1SKBUIwDoyJhacplAuaEjKnMeMw4_zwl4zDP40wKMSIX3n8FnqY5PycjmkoJnGZj8vjmqka7fWT3vsG2c26DOnqIZvZHtwZ9VLXRVvebbo0t-spHurVRo1u9xoD3l-Ss1LXHq6FPyMfz0_v8JV6uFq_z2TI2PGN9nIM2FmUxRWZTygALzSxwLplJKWgUheTUSgNmSm1uQRpRCoMit0WWQzblE3J32Lt13fcOfa-ayhusa91it_MqlWmecSEC-HAAjeu8d1iq7eFBRUH92VNAVbCnjvbUvz0FJoSvhyu7okF7jA66AnA7ANobXZcuOKr8kZPBMA-KfwFcbnhp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68697344</pqid></control><display><type>article</type><title>Primary dysmenorrhea : Advances in pathogenesis and management</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>YUSOFF DAWOOD, M</creator><creatorcontrib>YUSOFF DAWOOD, M</creatorcontrib><description>Primary dysmenorrhea is painful menstrual cramps without any evident pathology to account for them, and it occurs in up to 50% of menstruating females and causes significant disruption in quality of life and absenteeism. Current understanding implicates an excessive or imbalanced amount of prostanoids and possibly eicosanoids released from the endometrium during menstruation. The uterus is induced to contract frequently and dysrhythmically, with increased basal tone and increased active pressure. Uterine hypercontractility, reduced uterine blood flow, and increased peripheral nerve hypersensitivity induce pain. Diagnosis rests on a good history with negative pelvic evaluation findings. Evidence-based data support the efficacy of cyclooxygenase inhibitors, such as ibuprofen, naproxen sodium, and ketoprofen, and estrogen-progestin oral contraceptive pills (OCPs). Cyclooxygenase inhibitors reduce the amount of menstrual prostanoids released, with concomitant reduction in uterine hypercontractility, while OCPs inhibit endometrial development and decrease menstrual prostanoids. An algorithm is provided for a simple approach to the management of primary dysmenorrhea.</description><identifier>ISSN: 0029-7844</identifier><identifier>EISSN: 1873-233X</identifier><identifier>DOI: 10.1097/01.AOG.0000230214.26638.0c</identifier><identifier>PMID: 16880317</identifier><identifier>CODEN: OBGNAS</identifier><language>eng</language><publisher>New York, NY: Elsevier Science</publisher><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Biological and medical sciences ; Contraceptives, Oral, Combined - administration & dosage ; Decision Trees ; Dysmenorrhea - diagnosis ; Dysmenorrhea - drug therapy ; Dysmenorrhea - physiopathology ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Humans ; Ibuprofen - administration & dosage ; Ketoprofen - administration & dosage ; Medical sciences ; Naproxen - administration & dosage ; Non tumoral diseases</subject><ispartof>Obstetrics and gynecology (New York. 1953), 2006-08, Vol.108 (2), p.428-441</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-90acde8b5e2d6120eba2d03382c610ae4b831d8c0c51d9d08c4f4ce49db790753</citedby><cites>FETCH-LOGICAL-c372t-90acde8b5e2d6120eba2d03382c610ae4b831d8c0c51d9d08c4f4ce49db790753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18001369$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16880317$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YUSOFF DAWOOD, M</creatorcontrib><title>Primary dysmenorrhea : Advances in pathogenesis and management</title><title>Obstetrics and gynecology (New York. 1953)</title><addtitle>Obstet Gynecol</addtitle><description>Primary dysmenorrhea is painful menstrual cramps without any evident pathology to account for them, and it occurs in up to 50% of menstruating females and causes significant disruption in quality of life and absenteeism. Current understanding implicates an excessive or imbalanced amount of prostanoids and possibly eicosanoids released from the endometrium during menstruation. The uterus is induced to contract frequently and dysrhythmically, with increased basal tone and increased active pressure. Uterine hypercontractility, reduced uterine blood flow, and increased peripheral nerve hypersensitivity induce pain. Diagnosis rests on a good history with negative pelvic evaluation findings. Evidence-based data support the efficacy of cyclooxygenase inhibitors, such as ibuprofen, naproxen sodium, and ketoprofen, and estrogen-progestin oral contraceptive pills (OCPs). Cyclooxygenase inhibitors reduce the amount of menstrual prostanoids released, with concomitant reduction in uterine hypercontractility, while OCPs inhibit endometrial development and decrease menstrual prostanoids. An algorithm is provided for a simple approach to the management of primary dysmenorrhea.</description><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Contraceptives, Oral, Combined - administration & dosage</subject><subject>Decision Trees</subject><subject>Dysmenorrhea - diagnosis</subject><subject>Dysmenorrhea - drug therapy</subject><subject>Dysmenorrhea - physiopathology</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Ibuprofen - administration & dosage</subject><subject>Ketoprofen - administration & dosage</subject><subject>Medical sciences</subject><subject>Naproxen - administration & dosage</subject><subject>Non tumoral diseases</subject><issn>0029-7844</issn><issn>1873-233X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1Lw0AQhhdRbK3-BQmC3hJnP5psPAilaBUK9aDgbdnsTtpIPupuKvTfu9pA5zKHed4Z5iHkhkJCIc_ugSaz1SKBUIwDoyJhacplAuaEjKnMeMw4_zwl4zDP40wKMSIX3n8FnqY5PycjmkoJnGZj8vjmqka7fWT3vsG2c26DOnqIZvZHtwZ9VLXRVvebbo0t-spHurVRo1u9xoD3l-Ss1LXHq6FPyMfz0_v8JV6uFq_z2TI2PGN9nIM2FmUxRWZTygALzSxwLplJKWgUheTUSgNmSm1uQRpRCoMit0WWQzblE3J32Lt13fcOfa-ayhusa91it_MqlWmecSEC-HAAjeu8d1iq7eFBRUH92VNAVbCnjvbUvz0FJoSvhyu7okF7jA66AnA7ANobXZcuOKr8kZPBMA-KfwFcbnhp</recordid><startdate>20060801</startdate><enddate>20060801</enddate><creator>YUSOFF DAWOOD, M</creator><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060801</creationdate><title>Primary dysmenorrhea : Advances in pathogenesis and management</title><author>YUSOFF DAWOOD, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-90acde8b5e2d6120eba2d03382c610ae4b831d8c0c51d9d08c4f4ce49db790753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Contraceptives, Oral, Combined - administration & dosage</topic><topic>Decision Trees</topic><topic>Dysmenorrhea - diagnosis</topic><topic>Dysmenorrhea - drug therapy</topic><topic>Dysmenorrhea - physiopathology</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Ibuprofen - administration & dosage</topic><topic>Ketoprofen - administration & dosage</topic><topic>Medical sciences</topic><topic>Naproxen - administration & dosage</topic><topic>Non tumoral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YUSOFF DAWOOD, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YUSOFF DAWOOD, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Primary dysmenorrhea : Advances in pathogenesis and management</atitle><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle><addtitle>Obstet Gynecol</addtitle><date>2006-08-01</date><risdate>2006</risdate><volume>108</volume><issue>2</issue><spage>428</spage><epage>441</epage><pages>428-441</pages><issn>0029-7844</issn><eissn>1873-233X</eissn><coden>OBGNAS</coden><abstract>Primary dysmenorrhea is painful menstrual cramps without any evident pathology to account for them, and it occurs in up to 50% of menstruating females and causes significant disruption in quality of life and absenteeism. Current understanding implicates an excessive or imbalanced amount of prostanoids and possibly eicosanoids released from the endometrium during menstruation. The uterus is induced to contract frequently and dysrhythmically, with increased basal tone and increased active pressure. Uterine hypercontractility, reduced uterine blood flow, and increased peripheral nerve hypersensitivity induce pain. Diagnosis rests on a good history with negative pelvic evaluation findings. Evidence-based data support the efficacy of cyclooxygenase inhibitors, such as ibuprofen, naproxen sodium, and ketoprofen, and estrogen-progestin oral contraceptive pills (OCPs). Cyclooxygenase inhibitors reduce the amount of menstrual prostanoids released, with concomitant reduction in uterine hypercontractility, while OCPs inhibit endometrial development and decrease menstrual prostanoids. An algorithm is provided for a simple approach to the management of primary dysmenorrhea.</abstract><cop>New York, NY</cop><pub>Elsevier Science</pub><pmid>16880317</pmid><doi>10.1097/01.AOG.0000230214.26638.0c</doi><tpages>14</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0029-7844 |
ispartof | Obstetrics and gynecology (New York. 1953), 2006-08, Vol.108 (2), p.428-441 |
issn | 0029-7844 1873-233X |
language | eng |
recordid | cdi_proquest_miscellaneous_68697344 |
source | MEDLINE; Journals@Ovid Complete |
subjects | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Biological and medical sciences Contraceptives, Oral, Combined - administration & dosage Decision Trees Dysmenorrhea - diagnosis Dysmenorrhea - drug therapy Dysmenorrhea - physiopathology Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Ibuprofen - administration & dosage Ketoprofen - administration & dosage Medical sciences Naproxen - administration & dosage Non tumoral diseases |
title | Primary dysmenorrhea : Advances in pathogenesis and management |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T23%3A48%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Primary%20dysmenorrhea%20:%20Advances%20in%20pathogenesis%20and%20management&rft.jtitle=Obstetrics%20and%20gynecology%20(New%20York.%201953)&rft.au=YUSOFF%20DAWOOD,%20M&rft.date=2006-08-01&rft.volume=108&rft.issue=2&rft.spage=428&rft.epage=441&rft.pages=428-441&rft.issn=0029-7844&rft.eissn=1873-233X&rft.coden=OBGNAS&rft_id=info:doi/10.1097/01.AOG.0000230214.26638.0c&rft_dat=%3Cproquest_cross%3E68697344%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68697344&rft_id=info:pmid/16880317&rfr_iscdi=true |